Key Highlights

  • Xeris Biopharma (NASDAQ:XERS) closed at USD 13.17 in a published market data snapshot, up 25.91% in the latest session, with 21.94% over one week, 28.74% over one month, 77.25% over three months and 100.46% over six months.
  • Third quarter Revenue climbed 44% to USD 107.2 million from USD 74.4 million, and Recorlev sales surged 93% to USD 71.5 million, while Net Income reached USD 11.3 million against USD 0.6 million.
  • Management lifted 2026 total revenue guidance to USD 395 million to USD 405 million and raised its 2030 outlook to more than USD 1 billion from about USD 750 million.
  • At the snapshot price the calculated Market Value sits near USD 2.41 billion, a figure that moves the stock from the small cap range into the Mid cap bucket of USD 2 billion to USD 10 billion.

Third Quarter Product Sales and Margin Detail

Xeris Biopharma (NASDAQ:XERS) posted its third quarter 2026 figures at 7:00 a.m. ET on November 5, 2026, and the stock jumped 25.91% in that session, from USD 10.46 to USD 13.17. Sales reached USD 107.2 million, an increase of 44%, and product revenue alone was USD 106.3 million, up 43%. The Recorlev line delivered USD 71.5 million, nearly double the USD 37.0 million of a year before, Keveyis brought USD 13.0 million, and Gvoke dropped to USD 21.7 million, a 14% decline. Gross margin improved to 88%, and adjusted EBITDA hit USD 30.75 million, up from USD 17.4 million. Profit for the period came to USD 11.3 million, or USD 0.06 a share, compared with USD 0.6 million previously.

Raised Targets and a Stronger Balance Sheet

A product-led beat and a higher top-line forecast combined to move the shares. Management now expects full-year 2026 sales between USD 395 million and USD 405 million, and nine month sales of USD 282.5 million, which rose 37%, support that band. The long-range 2030 target was pushed above USD 1 billion, previously near USD 750 million, reshaping how investors model future earnings. The Balance Sheet also firmed: cash climbed to USD 131.1 million from USD 111.0 million at the end of last year, long-term borrowings declined to USD 189.7 million from USD 220.3 million, and the 2028 convertible notes were repaid on July 15, 2026, eliminating roughly USD 34 million of debt.

Valuation, Single-Product Dependence and Reversal Risk

Monthly, quarterly and half-year returns of 28.74%, 77.25% and 100.46% imply the shares have about doubled since spring, and no year to date number appears in the snapshot. Using 182,700,038 shares outstanding and a float near 176.33 million, the calculated market value is about USD 2.41 billion, compared with about USD 1.91 billion at the earlier USD 10.46 price. Recorlev produced roughly 67% of product revenue in the quarter (simple arithmetic), and Gvoke is in decline. Following a rise this steep, a handful of trades can shift the price, spreads may be wide, and a reversal is possible. Average Volume and the 52-week range were not available.

Where Things Stand

Recorlev demand, together with higher 2026 and 2030 targets, appears to be what pushed it higher. Xeris Biopharma (NASDAQ:XERS) rose because those results arrived with raised targets, and it now ranks among the best performing mid caps of the past week at a 21.94% weekly gain, with 1-month and 6-month gains of 28.74% and 100.46%. The crossing of the USD 2 billion threshold, by calculation, moved it out of the small cap range. This is context, not a forecast or advice.